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Abstract
Chronic liver disease has become a global health problem 
as a result of the increasing incidence of viral hepatitis, 
obesity and alcohol misuse. Over the past three decades, 
in the United Kingdom alone, deaths from chronic liver 
disease have increased both in men and in women. 
Currently, 2.5% of deaths worldwide are attributed to 
liver disease and projected figures suggest a doubling in 
hospitalisation and associated mortality by 2020. Chronic 
liver diseases vary for clinical manifestations and natural 
history, with some individuals having relatively indolent 
disease and others with a rapidly progressive course. 
About 30% of patients affected by hepatitis C has a 
progressive disease and develop cirrhosis over a 20 years 
period from the infection, usually 5-10 years after initial 
medical presentation. The aim of the current therapeutic 
strategies is preventing the progression from hepatitis 
to fibrosis and subsequently, cirrhosis. Hepatic steatosis 
is a risk factor for chronic liver disease and is affecting 
about the half of patients who abuse alcohol. Moreover 
non-alcoholic fatty liver disease is part of the metabolic 
syndrome, associated with obesity, hypertension, type 
Ⅱ diabetes mellitus and dyslipidaemia, and a subgroup 
of patients develops non-alcoholic steatohepatitis and 
fibrosis with subsequent cirrhosis. The strengths and 
pitfalls of liver biopsy are discussed and a variety of 
new techniques to assess liver damage from transient 
elastography to experimental techniques, such as in 
vitro  urinary nuclear magnetic resonance spectroscopy. 
Some of the techniques and tests described are already 
suitable for more widespread clinical application, as is 
the case with ultrasound-based liver diagnostics, but 
others, such as urinary metabonomics, requires a period 
of critical evaluation or development to take them from 
the research arena to clinical practice.
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assessment of liver disease. New techniques to assess 
liver damage from transient elastography to experimental 
techniques, such as in vitro  urinary nuclear magnetic 
resonance spectroscopy are currently investigated. 
The guidelines of sustainability in countries with limited 
resources, facilities and low financial income can be seen 
as an opportunity for addressing research toward low-
cost diagnostics and for driving clinical practice toward 
more streamlined technology, with ultimate benefits for 
the populations of poorer countries around the world. In 
this perspective, urinary biomarkers of liver cancer and 
ultrasound imaging are two complementary models. 
Trovato FM, Tognarelli JM, Crossey MME, Catalano D, Taylor-
Robinson SD, Trovato GM. Challenges of liver cancer: Future 
emerging tools in imaging and urinary biomarkers. World J 
Hepatol 2015; 7(26): 2664-2675  Available from: URL: http://
www.wjgnet.com/1948-5182/full/v7/i26/2664.htm  DOI: http://
dx.doi.org/10.4254/wjh.v7.i26.2664
INTRODUCTION
“Nothing strengthens authority so much as silence”: 
Leonardo da Vinci
Many relevant reviews are available on chronic liver 
disease and on one of its major complications, hepa­
tocellular carcinoma (HCC), and the most significant 
advances in diagnosis, management, and long­term
outcome are appropriately considered and well­focused[1]. 
By contrast, this brief overview has the aim of sum­
marizing some epidemiological and clinical concepts, 
highlighting some of the current diagnostic criteria used 
for addressing personalized therapeutic choices, and 
discussing briefly some practical and ethical challenges. 
The latter problems are also the consequence of a global 
economy and of the current research approach, which 
we have to consider from the perspective of sustai­
nability[2]. 
The most frequent liver cancer, accounting for 
80%­90% of all primary liver cancers, is HCC, but there 
are critical differences in the diagnostic algorithms. 
Differences are due not only to the skills and knowledge 
of pathologists, but also to the actual availability of 
such diagnostic facilities in most countries, particularly 
where liver cancer is more frequent. Sadly, there are 
countries in which only one surgical pathology laboratory 
is available: This is the case of Zambia, a country with 
12 million inhabitants, while until recently, Liberia had no 
diagnostic laboratory services, owing to the ravages of 
a prolonged civil war. With this limitation and shortage 
of expertise, frequent even in developed countries, 
surrogate tools for reliable diagnosis are warranted, 
beside the fact that reducing the number of invasive 
procedures also has great appeal. The Italian Association 
of Pathologists, “Patologi Oltre Frontiera”, has been 
working in Africa since 2004 to create a virtual laboratory 
with telemedicine[3]. This is a very important approach, 
equally useful in countries with large populations, such 
as China[4]. The use of this approach as a continuous 
tool for training, by plain e­learning technology, provides 
valuable results in both the developed and the develop­
ing world[5,6], while new developments using emerging 
e­learning technologies and smartphone applications 
are steadily becoming a reality. In general, international 
research partnerships and potential clinical applications 
are receiving ever greater attention, given that techn­
ology has diminished the restriction of geographical 
barriers with the effects of globalisation becoming more 
evident, and populations increasingly more mobile[7]. 
The implications are manifold, and among them, 
the opportunity of assessing new diagnostic tools where 
there are emerging or more prevalent diseases, such as 
viral hepatitis, non­alcoholic fatty liver disease (NAFLD) 
and liver cancer. In this setting, international collaboration 
should move research goals away from pure market 
forces and towards humanitarian aims. Indeed, en­
compassing this second aim, the profession and the 
mission of medical intervention will contribute to peaceful 
cohesion and ultimately to shared economic profits.   
The pathophysiology of HCC has been attributed to 
chronic inflammation associated with a variety of disease 
processes, but on a worldwide scale, mainly due to viral 
hepatitis B virus (HBV) and hepatitis C virus (HCV). 
Nonetheless, cirrhosis is not the absolute pre­condition 
for the further development of cancer. HCC onset is 
associated with active HBV or HCV infection, but also 
its incidence increases with age, alcohol consumption, 
smoking, human immunodeficiency virus (HIV) infection, 
obesity and diabetes. In this regard, the concurrent effect 
of NAFLD is becoming all the more important, owing to 
an increasingly obese population, not only in Western 
Europe and North America, but also in the developing 
world[8]. Since it is possible to reverse much of the 
pathology seen in fatty liver disease through lifestyle 
change, such as exercise and dietary modification[9,10], 
it is quite surprising that the two paths of research and 
therapeutic intervention are not more closely allied in a 
translational approach, as in many places they are still 
separated, much like the tracks of a railroad[11]. 
The increase seen in chronic liver disease and HCC, 
confirmed and increasing in Europe for 20 years or 
more, is due to a multiplicity of factors, and not just to 
HCV­induced hepatitis[12]. The same increasing trend 
of incidence, possibly due to improved diagnostic tools, 
is reported worldwide for cholangiocarcinoma[13], the 
causes of which[14] are even less directly attributable 
to the same factors as HCC[15]. Cholangiocarcinoma is 
more insidious in its onset, with elusive clinical features 
devastating and scarcely responsive clinical progress. 
It is clear that a strategy for eradication of HBV and 
prevention of its consequences must include an effective 
campaign of successful widespread vaccination, with 
birth dose vaccination in the developing world, owing 
to the high prevalence of mother to baby transmission. 
As this is not possible yet for HCV infection, antiviral 
therapy regimens for HCV have been burdensome for 
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the patient and expensive for healthcare systems, and 
until recently, with poor sustained viral response rates 
to antiviral medications. Nonetheless, overall there is 
only weak evidence, if any, of a beneficial effect of viral 
eradication on the subsequent occurrence of liver cancer 
in such treated patients with cirrhosis[16]. 
The mainstay of diagnosis has been liver biopsy 
for many years, but now a variety of alternatives are 
beginning to emerge.
Liver biopsy techniques
A liver aspirate was performed for the first time in 
1883 by a German physician, Paul Ehrlich, while the 
percutaneous liver biopsy technique dates back to the 
1920s. Fifty years later the radiologist Charles Dotter 
invented the transjugular approach[17]. Several pre­
procedural precautions need to be taken, including prior 
knowledge of the patient’s anatomy with a screening 
liver ultrasound, an up­to­date platelet count and a 
clotting screen. Many conditions, such as high bleeding 
risk, are contraindications to standard percutaneous 
approaches, partially or completely[18]. However, liver 
biopsy remains the gold­standard for assessing the 
severity of chronic liver diseases.
Requirement for biomarkers of liver fibrosis 
Effective antiviral therapies and the advent of antifibrotic 
drugs have led to an increasing demand for non­invasive, 
accurate and reliable biomarkers of hepatic disease 
severity. It is recognised that the current “gold standard” 
for monitoring the severity of fibrosis, histological analysis 
of liver biopsy, has limitations and engenders risk to the 
patient with a defined morbidity, including pain, bleeding, 
time off work and a mortality rate of between one in 1000 
and one in 10000 cases[18]. The specimen retrieved by 
standard liver biopsy is just 1/50000 of the total volume 
of the liver, and in about 16% of cases the sample 
exceeds the optimal length for adequate histological 
assessment of 25 mm[19]. This causes sampling varia­
bility and errors since inflammation, hepatic fibrosis and 
steatosis may all have an irregular distribution within the 
liver. In addition, as histological scoring systems are semi­
quantitative categorical assessments of a continuous 
process (fibrogenesis), there is appreciable intra­ and 
inter­ observer variability.
A safe, reliable, non­invasive imaging approach for 
detecting hepatic fibrosis would obviate the hazards 
associated with liver biopsy and allow patients to be 
monitored serially with a view to prevent the decline 
towards cirrhosis and its complications. Accordingly, there 
are potential health economic benefits from prevention 
of end­stage disease and the reversal of less severe 
fibrosis.
Non-invasive assessment of chronic liver diseases
The non­invasive assessment of the severity of chronic 
liver disease includes the development of serum (or 
blood) markers, which may be divided into direct or 
indirect tests, either singly, or combined as serum panel 
markers, and the application of imaging­based tech­
nologies, such as ultrasound and magnetic resonance 
(MR) techniques. 
Serum markers
Serum may be obtained at routine venepuncture, 
making it quick and acceptable to most patients. Samp­
ling variability is negated, although site­specificity to 
hepatic processes may be questioned. Serum markers 
may broadly be divided into indirect and direct markers 
of hepatic fibrosis. Indirect markers are those where 
the indices measured correlate with fibrosis stage, 
but are not integral to the pathogenesis of disease. 
Such markers include “so­called” liver function tests, 
such as aspartate aminotransferase (AST) and alanine 
aminotransferases, and composite or panel markers, 
such as the AST­to­platelet ratio index (APRI) and the 
fibrotest/actitest markers. 
On the other hand, direct markers are those measu­
ring intermediates or metabolites of fibrogenesis, such as 
hyaluronic acid and panel markers such as the Enhanced 
Liver Fibrosis test, consisting of metalloproteinase­1, 
procollagenase 3 and hyaluronic acid. The performance 
of a number of these tests for the detection of cirrhosis 
is displayed in Table 1[20]. 
Imaging-based markers
Imaging techniques, particularly those based on 
ultrasound and MR, often provide hepatic structural 
information. Although a number of structural changes are 
associated with cirrhosis and portal hypertension, these 
signs alone are neither sensitive nor specific enough 
to stage chronic liver disease. A number of specialized 
applications have, however, shown promise and imaging 
techniques have the added benefit of providing real-time 
information to the operator and patient.
Transient elastography
Transient elastography is an ultrasound based technique 
that evaluates the velocity of propagation of a low­
frequency shear wave through the liver (Figure 1). 
This is dependent on the “stiffness” of the liver and 
reflects the degree of fibrosis. FibroScan® (Echosens, 
Paris, France) is the equipment dedicated to apply this 
technology and its performance has been scrutinised in 
a large number of studies over the last decade[21].  
However, while transient elastography performs 
well for the assessment of cirrhosis, with sensitivity 
and specificity quoted between 77% and 100%, there 
has been less clear separation of stages of pre­cirrhotic 
disease[21]. Cut­off values reported by different studies 
to assess histological stages are variable according to 
the kind of patients selected and aetiology of disease. 
More recently, liver stiffness has been shown to 
increase in flares of viral hepatitis and in acute hepati-
tis, even up to the levels seen in cirrhosis, but in the 
absence of clinically significant fibrosis. Further studies 
have demonstrated a compelling correlation between 
liver stiffness and portal pressure, while cardiac failure, 
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with shorter arrival times correlating with increased 
severity of liver disease due to circulatory changes, 
such as arterialisation of liver sinusoids, hyperdynamic 
circulation and extra­ and intra­hepatic shunting (Figure 
2). A study on 85 chronic hepatitis C patients assessed 
by HVTT showed 100% sensitivity and 80% specificity 
for cirrhosis[22]. Moreover microbubbles allowed to 
stratify mild and moderate disease (95% sensitivity 
and 86% specificity) suggesting that other processes, 
besides portal hypertension, may contribute to effects 
observed. 
MR techniques
Both MR imaging (MRI) and MR spectroscopy (MRS) 
techniques have been applied to assess the severity of 
chronic liver diseases[23]. MRI techniques include dynamic 
superparamagnetic iron oxide and gadolinium enhan­
ced studies, which have been shown to demonstrate 
reticular­nodular patterns, thought to represent septal 
hepatic fibrosis, allowing the qualitative discrimination of 
moderate to severe, from mild fibrosis. Objective stratifi-
cation of fibrosis severity in patients with chronic hepatitis 
C has been reported using diffusion­weighted MRI[24]. 
Furthermore, MR elastography, which like transient 
elastography measures liver stiffness, allows visualisation 
of a map of hepatic liver stiffness[25]. MRS examines the 
chemico­physical environment of nuclei in a region of 
interest, providing metabolic information in the form of a 
spectrum, of relevance in chronic liver disease. 
MR spectroscopy
In vivo 31P MRS is a safe, reproducible technique which 
provides biochemical information on hepatic metabolic 
processes. Typical in vivo 31P MR liver spectra contain 
phosphomonoester (PME), phosphodiester (PDE), 
inorganic phosphate (Pi) and ATP resonances, reflecting 
cellular energy state, intermediates of carbohydrate 
metabolism, precursors of cell membrane synthesis and 
breakdown. These resonances are multicomponent, but 
more detailed biochemical information may be obtained 
with in vitro MRS at higher magnetic field strengths (11.7 
T­14.0 T) than in clinical studies (1.5 T­3.0 T). 
In vivo phosphorus­31 (31P) MRS provides metabolic 
information useful to evaluate fibrogenesis. The PME/
PDE ratio has been used as an index of cell membrane 
infiltrative conditions and even hepatic steatosis may 
affect stiffness values. 
On the contrary of what was initially assumed, the 
sole liver stiffness cannot be considered a measure 
of hepatic fibrosis, but rather the result of different 
processes including fibrosis. Thus the results should be 
interpreted according to the clinical context and corro­
borated by other non­invasive techniques.
Use of ultrasound contrast agents
Microbubble contrast agents are small, stabilised gas­
filled phospholipid bubbles (about 3 µm) that resonate 
when subjected to ultrasound, amplifying the reflected 
signal, thus enhancing intravascular signal for several 
minutes after intravenous injection and increasing signal 
from vessels and tissues. Safety and tolerance with 
current agents is excellent. When quantified, the resultant 
signal intensity change is proportional to microbubble 
concentration[22]. 
A simple microbubble­enhanced ultrasound test to 
measure hepatic vascular transit time (HVTT) by timing 
the arrival of contrast agent in the hepatic artery and 
subsequently the hepatic vein has been developed. A 
curve of signal intensity against time can be plotted, 
Figure 1  Transient elastography. A specialist nurse places the probe per­
pendicular to the surface of the liver. A low frequency shear wave is generated 
along the same axis as the ultrasound transducer. The velocity of the shear wave 
through the liver is measured by a high frequency ultrasound signal and the 
output displayed as stiffness, in kPa, alongside a two­dimensional “elastogram”. 
The output is the median of 10 measurements, with a success rate of > 66% 
and an interquartile range of measurements < 1/3 of the median considered 
satisfactory.
Table 1  Examples of serum markers for the assessment of fibrosis
Name Constituents Accuracy (%)
Se Sp PPV NPV
Indirect markers
   APRI AST, platelets 41 95 88 64
   FibroTest α2 macroglobulin, α2 and γ globulin,  total bilirubin, apolipoprotein A1, γGT 87 59 63 85
Direct markers
   ELF PⅢNP, HA, TIMP-1, (age)    90.5 41 99 92
   FibroSpect HA, TIMP-1, γ2 macroglobulin 77 73 74 76
APRI: Aspartate aminotransferase (AST) to platelet ratio index; γGT: γ-glutamyl transpeptidase; HA: Hyaluronic acid; PⅢNP: Amino terminal of 
procollagenase Ⅲ; TIMP-1: Tissue inhibitor of matrix metalloproteinase 1; ELF: Enhanced Liver Fibrosis test; Se: Sensitivity; Sp: Specificity; PPV: Positive 
predictive value; NPV: Negative predictive value.
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turnover and correlates with histological stages. MRS 
has good sensitivity (82%) and specificity (81%) to 
detect cirrhosis and could differentiate it from mild 
hepatitis and moderate hepatitis[26] (Figure 3). 
Recent longitudinal work in chronic hepatitis C has 
demonstrated a change in PME/PDE ratios in response 
to antiviral treatment, separating virological responders 
from non­responders. 
MRS in hepatic steatosis
In hepatic steatosis, proton (1H) MRS can provide 
information on the amount of liver fat[27]. More recent 
studies have demonstrated the potential to measure 
lipid composition non­invasively, which may change 
with disease state and with dietary intervention. Typical 
hepatic spectra contain water, fat and choline resonances, 
which can be quantified using external reference stand-
ards or expressed as a percentage relative to the total 
MR signal (Figure 4). 1H MRS is readily accessible to all 
centres that have an MR scanner and most machines 
have the capability to perform such sequences as an 
addition to a standard MRI examination. 
The future of biomarkers of chronic liver disease
Inflammation, steatosis and fibrosis are complex mul­
tistep processes. It would be surprising if a single 
biomarker were able to describe liver disease completely. 
Accordingly, combinations of markers and modalities 
may describe disease more accurately and reproducibly 
than one marker alone. Studies of marker combinations 
should be performed to establish optimal combinations, 
in terms of numbers of tests, accuracy of combinations 
and the provision of complementary information from 
the test components. Candidate markers differ widely in 
the equipment and expertise required, so cost­benefit 
analyses compared to routine liver biopsy are warranted. 
Serum markers and imaging techniques need to be 
investigated longitudinally in response to intervention in 
a number of disease states. As histological assessment 
of liver biopsy is itself a surrogate marker of liver disease, 
the challenge is to develop and validate protocols 
correlated to clinically meaningful outcome measures. 
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Figure 2  Hepatic vascular transit times. Time intensity curves from the hepatic vein plotted in a normal patient and a patient with cirrhosis, showing earlier arrival of 
contrast in the cirrhotic liver. Adapted from Lim et al[22] 2005. HVTT: Hepatic vascular transit times.
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Figure 3  31P magnetic resonance spectroscopy. PME/PDE ratios obtained 
from in vivo hepatic 31P MRS varying with severity of hepatitis C­associated 
liver disease.  Adapted from Lim et al[26] 2003. MRS: Magnetic resonance 
spectroscopy; PME: Phosphomonoester; PDE: Phosphodiester.
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Further research into non­invasive technologies for 
the assessment of chronic liver disease is required to 
correlate these techniques with clinical outcomes and to 
optimise them, in order to create validated management 
algorithms.
The challenge of a reliable diagnosis by non-invasive 
imaging 
“Don’t spend time beating on a wall, hoping to 
transform it into a door” Coco Chanel: According 
to the United States Center for Disease Control, May 
2015, (http://www.cdc.gov/hepatitis/HCV/HCVfaq.
htm#section1) every 100 persons infected with HCV, 
75­85 will go on to develop chronic infection, 60­70 
will develop chronic liver disease and over a period of 
20­30 years 5%­20% will become cirrhotic. The death 
for liver disease, for cirrhosis or liver cancer involves the 
1%­5% of patients infected, since the yearly incidence 
of HCC in people with cirrhosis is 3%­5%. This is very 
similar to the recommendation of WHO, which specifies 
that development of HCC is rare in patients with chronic 
hepatitis C not complicated by cirrhosis (http://www.
who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/
index3.html). 
The current treatment indications for HCV are under a 
state of flux, owing to the advent of a raft of new directly-
acting antiviral agents (DAAs). The current modus 
vivendi is to allow the use of new drugs according to the 
presence of severe grades of fibrosis in some countries, 
but decompensating cirrhosis in others[17,28]. The grade 
of fibrosis can be assessed by liver biopsy, but modern 
algorithms now allow the use of non­invasive ultrasound 
procedures, such as transient elastography (Fibroscan
®) and Acoustic Radiation Force Impulse (ARFI), two 
methods suitable for measuring the “stiffness” of the liver 
(LSM). 
In the United States, as in Italy, there are reference 
criteria, i.e., cut-off values, for defining the presence of 
severe fibrosis. For instance, according to the criteria 
of the Harvard Pilgrim Health Care, LSM of ≥ 7.5 kPa 
on Fibroscan® should allow the use of DAAs; while 
according to the Idaho criteria Fibroscan® measurement 
> 12.5 kPa or ARFI value > 1.75 m/s or APRI score 
> 1.5 should be used. These striking differences are 
mirrored by the different results reported in the past 
and are well discussed in the EASL­AASLD clinical 
practice guidelines[29]. These variances in cut­off values 
for treatment are all the more complicated, given how 
prone the “gold standard”, liver biopsy, is to sampling 
error and underscoring of fibrosis[18,19]. 
With this in mind, we set out to define the non­
invasive measures most suitable to be used as cut­
off values to define cirrhosis in a prospective case­
control study, taking into account co­temporaneous liver 
biopsies, ARFI and TE measurements in chronic liver 
disease with different severity of fibrosis, measured by 
the Ishak grading system. Patients with liver cancer 
were excluded. According to the results in our patients, 
there is optimal correlation of the non­invasive measures 
of fibrosis, either ARFI or Fibroscan®, with each other 
and with the Ishak score. The cut­off values for cirrhosis 
that we identified are: ≥ 10.25 kPa for Fibroscan®, and 
ARFI of the left liver lobe m/s 1.77, ARFI of the right liver 
lobe m/s. 1.92 for the overall group of patients. These 
cut­off values for the presence of cirrhosis were lower in 
subjects with previous HBV, compared to HCV, and even 
lower in subjects without any evidence of viral hepatitis, 
such as NAFLD. This observation strengthens the need 
of using the chosen cut-off for specific disease groups.
Differently, detection of liver nodules by any imaging 
method, particularly by ultrasound, is a defendable 
screening procedure, even if it encounters several limita­
tions. It is suggested that combining alpha­fetoprotein 
(AFP) with ultrasound is the method of choice for 
screening patients at high risk for developing HCC, but 
this is not a widely accepted criterion due to the lack of 
sensitivity and specificity[30]. The use of plain ultrasound, 
even without contrast, is still the most suitable approach. 
Small nodules (< 1 cm) should be followed up in 3 
subsequent months repeating ultrasound. If the lesion 
is no longer detectable, or if it is stable, it should be 
watched every 3 mo according to a monitoring strategy. 
In the case that the nodule enlarges, further imaging 
is needed. Equally, nodules that are > 1 cm require 
an immediate work up with computed tomography or 
MRI[31]. Despite the great interest and intervention aimed 
at screening HCC in high­risk populations[32­34], the actual 
results are controversial and, more importantly, the cost­
benefit ratio in terms of outcome is still disputed[35,36]. 
This is the current situation, despite the benefits of the 
use of effective drugs[37­39] and, to a lesser degree, of 
IHCL CH2
Water
7.0              5.0              3.0              1.0              -1.0
ppm
Figure 4  1H magnetic resonance spectroscopy. Proton (1H) MR Spectra 
(left to right) from: (1) a patient with significant hepatic steatosis; (2) a patient 
with mild hepatic steatosis; and (3) a healthy volunteer. The intrahepatocellular 
(IHCL) lipid resonance is many times larger in (1) than (3), with the hepatic 
water resonance scaled to the same height for comparative purposes. 
Candidate markers for hepatocellular carcinoma which have been proposed 
in the literature. Most reflect high cellular turnover exhibited by tumours, but 
the majority lack sensitivity and specificity (see text for further explanations). 
Reproduced from Thomas et al[27] 2005. ppm: Parts per million; IHCL CH2: 
Intrahepatocellular lipid.
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United States­guided treatments. Of course, surgical 
procedures are still the first line therapy in appropriate 
settings. Unfortunately, this is not the most frequent 
situation, less than 20% are suitable candidates for 
resection due to either multifocal unresectable tumors 
or their underlying chronic liver disease[1]. In this subset 
pharmacological therapy, with the current available drugs 
and other emerging molecules or associations, which will 
be available in the future, remains the more sustainable 
and rewarding option. The use of biomarkers, also 
derived from proteomic profiles, was found to have some 
utility in the prediction of clinical response to therapy[40], 
but other investigations in this field are needed.
SUSTAINABLE AND RELIABLE 
DIAGNOSIS: THE PLACE OF URINARY 
BIOMARKERS FOR LIVER CANCER 
DIAGNOSIS
Better three hours too soon than a minute too late. 
William Shakespeare
Urine has long been known to possess diagnostic fea­
tures; Indian scriptures reporting its sweet taste are 
probably the earliest proof of this. In the ⅩⅦ century, 
Thomas Willis identified the sweet taste of urine in 
diabetic polyuria. These characteristics have been used 
in daily practice since the diagnostic potential of urine 
has been applied in dipstick reagents. Some examples 
are the diagnosis of proteinuria, through detection of 
protein amine groups; haematuria, thanks to peroxidise 
activity of lysis­released haemoglobin; infection, through 
the detection of leukocyte esterase and nitrites; glyco­
suria, thanks to the conversion to hydrogen peroxide 
by glucose oxidase and pregnancy, with a strip­based 
immunoassay for rapid determination of beta human 
chorionic gonadotropin[41,42].
Urinary biomarkers
To be a urinary biomarker, a substance must pass 
through the renal collecting system avoiding tubular 
re­absorption, after plasma filtration through the renal 
glomerulus thanks to its size and ionic charge. Indeed 
the renal glomerulus is a barrier for larger or negatively 
charged plasma proteins, like albumin, since only mole­
cules of < 20 kDa or 1.8 nm in size may pass through. 
Only after these passages can a molecule finally be found 
in enough quantities in urine to allow a diagnosis.
How select a good diagnostic test?
A good test must have high sensitivity (ideally 100%) 
and specificity, whilst also detecting the disease in its 
early stages, in order to allow the best treatment. “Gold 
standard” is the term used for the most accurate test 
that unfortunately is often expensive or time consuming 
to use for rapid diagnostics in the daily practice. So a 
good test must also be cheap, minimally invasive with 
low risk for the patient, and rapid, providing the needed 
information quickly, and allowing a management plan. 
In particular for HCC the early diagnosis is important as 
lesions detected below 2 cm are treatable with surgical 
resection or liver transplantation. Moreover HCC affects 
different populations, and the test should, be applicable 
across different patients and ethnicities.
The prevalence of HCC is high in the developing 
world[43], particularly in sub­Saharan Africa, where the 
attention to expense is of most importance, since often 
patients spent many days to reach a hospital and have 
limited resources to move. A urine dipstick test for HCC 
potentially would fulfil many of these criteria. 
How detect cancer through the urine?
A urine biomarker must have three main features: 
first, correct size (less than 20 kDa) and ionic charge 
to pass through the renal glomerulus and be not re­
absorbed by the tubules. Second, the biomarker should 
not be a molecule produced as a secondary effect of 
cancer, but needs to be specific for the type of cancer. 
Third, the amount of biomarker secreted should be 
adequate for early detection. The research of markers 
must be focused on small molecules (50­1000 Da) 
called metabolites, including bile acids, amino acids, 
peptides and nucleotides. Different combinations of 
metabolites could be specific for different conditions, 
while individually, since they are ubiquitous and involved 
in most cellular processes, they have minimal diagnostic 
potential. So a metabolic profile of different altered 
metabolites in combination may be highly specific for a 
type of cancer. This field of research has been termed 
“metabonomics”[44]. 
Urinary biomarkers of HCC
Nucleosides: The research for a urinary biomarker of 
HCC dates back to the 1970s when high levels of methy­
lated purines (7­methylguanine, 1­methylhypoxanthine, 
N­dimethylguanine, 1­methylguanine and adenine) were 
detected in the urine of patients with HCC compared 
to both cirrhotic patients and healthy controls[45] (Table 
2). This suggested that a rapid ribonucleic acid (RNA) 
turnover is involved in HCC pathogenesis and the methy­
lation of nucleic acid could be a potentially involved 
in carcinogenesis. Later, a study using immunoassay 
technique showed high urinary levels of cyclic guanosine 
3’:5’ monophosphate (cGMP) in rats with implanted liver 
and kidney tumours[46]. These findings were confirmed in 
1982 by Dusheiko et al[47] in a clinical study on humans. 
The urinary cGMP excretion, as well as the plasma and 
ascitic fluid levels of cGMP, were found to be increased 
in patients with HCC, hepatic disease and other neo­
plasms[47]. These findings supported the hypothesis of 
a shift in cyclic nucleotide metabolism toward cGMP in 
cancer. However, urinary cGMP is not accurate to detect 
progression of cirrhosis to HCC, nor to differentiate HCC 
from other cancers.
The case for nucleoside derivatives as tumour 
markers was supported in 1986 by Tamura et al[48] in 
their study in HCC patients using high performance 
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liquid chromatography (HPLC). They detected high level 
of urinary pseudouridine, a C­glycoside isomer of the 
nucleoside uridine,that showed a high sensitivity (83%) 
for HCC diagnosis if combined with serum AFP levels[48]. 
Urinary pseudouridine levels probably reflect the overall 
cellular proliferation in tumorigenesis and are not specific 
for HCC, since have also been shown to be elevated in 
other cancers, such as non­Hodgkin’s lymphoma.
Jeng et al[49] showed, with an HPLC­based study in 
Taiwanese subjects, that the nucleosides adenosine, 
cytidine and inosine were elevated in the urine of patients 
affected by HCC and if joined with serum levels of AFP, 
the diagnosis of cancer was reached with a sensivity 
of 80%[49]. However this study evaluated the potential 
markers of HCC comparing only with a healthy control 
group, not considering cirrhotic patients, decreasing the 
reliability of the study. 
Transforming growth factor α and β
In 1990, a study using a modified ELISA assay, showed 
the presence of transforming growth factor α (TGFα) in 
the urine of patients affected by HCC[50]. The following 
year a small study by Chuang et al[51] identified low 
molecular weight epidermal growth factor­related TGFs 
with functional activity in the urine of a similar group of 
patients. The same author corroborated their results in 
a larger study in 1997, showing a correlation of urinary 
TGFβ1 with the outcome of HCC patients[52]. A functional 
explanation of TGFs role in carcinogenesis comes from 
the ability to stimulate non­transformed cells to grow as 
colonies in vitro. However further studies are needed to 
confirm if these findings are specific for HCC compared 
to other malignancies. 
Neopterin
Neopterin is a protein released from macrophages 
during the inflammatory response. In 1998 authors 
showed increased urinary levels of neopterin in Japanese 
patients with advanced HCC, correlating with lesion 
size but not with AFP. However this protein was not 
detected in patients with early HCC[53,54]. Unfortunately, 
neopterin has been found to be elevated in several 
cancers and other inflammatory diseases such as HIV 
infection[55], thus it is not specific for the diagnosis of 
HCC. Conversely, the combination of HPLC urinary levels 
of neopterin, pseudouridine and creatinine is a reliable 
indicator of RNA turnover, indicating neoplastic growth, 
in adenocarcinoma, non­Hodgkin’s lymphoma and 
HCC[56]. 
Polyamines
The exact role of the polyamines (putrescine, spermine 
and spermidine) is unclear, although they are involved 
in cellular proliferation. Putrescine acts on S­adenosylme­
thionine (SAMe), a methylating molecule, to produce 
spermine, which in turn acts on further SAMe molecules 
to produce spermidine[57]. Antoniello et al[58], in their 
study based on reverse phase liquid chromatography, 
found increased levels of free and acetylated polyamines 
in the urine of patients affected by HCC compared to 
both healthy and disease controls (cirrhotic patients)[58]. 
As other biomarkers polyamines are not specific to HCC 
and not sensitive enough for early­stage diagnosis. 
Urinary trypsin inhibitor
Urinary trypsin inhibitor (UTI) is a 25 kDa trypsin 
inhibitor used as a marker of hepatocyte function, it 
is believed to be produced by hepatocytes. A study in 
2004 failed to shows a significant difference in levels 
of UTI in liver cirrhosis and HCC patients[59] reducing its 
usefulness in the early diagnosis of cancer. Other authors 
demonstrated that there is a correlation with the severity 
of liver disease, indeed Kikuchi et al[60] found a reduction 
of UTI plasmatic levels after HCC surgical treatment. 
Moreover the levels of UTI were correlated also with risk 
of tumour recurrence. Thus, UTI may be considered a 
biomarker of hepatic disorders and HCC but, also in this 
case, it lacks sensitivity for the early detection of cancer. 
Metabolic profiling
Wu et al[61], in their study based on urinary gas chroma­
tography mass spectrometry of 20 HCC patients, founda 
marker set of 18 metabolites (including octanedioic 
acid, glycine and hypoxanthine) distinguishing HCC and 
healthy Chinese controls, but a disease control group 
of cirrhotic patients was not considered[61]. This reduces 
the reliability of those findings in the principal at risk 
population. 
A recent proton magnetic resonance (1H­NMR) 
spectroscopy study by Shariff et al[62] reported a panel 
of urinary metabolites discriminating patients affected 
by HCC from both healthy controls and cirrhotic ones, 
with high sensitivity and specificity, respectively 100% 
and 93% in the first case and 89.5% and 88.9% in the 
second one, in a Nigerian groups of patients (Figure 5)[62]. 
This panel included creatine, creatinine, carnitine and 
acetone, that mirror an alteration of energy metabolism 
and cellular growth in such group of patients. Moreover, 
creatine is a biomarker of cachexia and sarcopenia 
related to the malignancy condition. These results need 
to be corroborated by larger studies on different ethnicity, 
Table 2  Urinary markers of hepatocellular carcinoma
Year Urinary biomarker 
Nucleosides and nucleotides 
   1974 Methylated purines[45]
   1976 Cyclic GMP[46,47]
   1986 Pseudouridine[48,49]
Proteins and polyamines 
   1990 TGFα and β[50-52]
   1998 Neopterin[53-56]
   2004 Urinary trypsin inhibitor[59,60]
   1998 Spermine, putrescine, spermidine[58]
Metabolite profiles 
   2009 Octanedioic acid, glycine and hypoxanthine[61]
   2010 Creatinine, carnitine, creatine[62]
GMP: Guanosine 3’:5’ monophosphate; TGF: Transforming growth factor.
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before this panel could be applicable and extended to the 
varying range of patients affected by HCC. 
The information contained in the urine is useful to 
reach the diagnosis and urinary dipsticks are used in 
daily practice, allowing the physician to institute rapid 
management of an underlying condition, ranging from 
urinary tract infections to pregnancy. A new urinary 
dipstick test for the diagnosis of HCC would be of great 
value both in developed countries, where the first 
screening could be done by general practitioners, and in 
the resource­poor settings, where patients may not have 
easy access to serological tests or imaging facilities. 
These are the essential raisons d’être for searching 
and using urinary biomarkers for the early and reliable 
diagnosis of HCC, but promising research is still being 
undertaken to this end (Figure 6). 
After preliminary studies[62­64] using urinary 1H­NMR
spectroscopy in African populations, multiple marker 
metabolites in the urine do provide clues for the im­
plication of altered energy­related pathways in the 
pathogenesis and progression of HCC[63]. More impor­
tantly from a clinical perspective, metabotypic changes 
seem to characterize HCC patients with enhanced 
sensitivity and specificity compared to serum AFP in the 
published studies to date, although much work needs 
to be performed on validation of this[64]. These findings 
suggest panel of urinary metabolites may prove useful 
for screening HCC in at­risk populations.
Moreover, further investigation in high risk populations 
for other liver cancers, such as cholangiocarcinoma[64], 
notably in Northeast Thailand[65], may be a worthwhile 
direction to pursue, potentially providing an answer 
to the difficult challenge of early diagnosis of primary 
cholangiocarcinoma and of monitoring the effects of 
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Figure 6  Statistical “loadings plot” of information obtained from an urinary nuclear magnetic resonance spectroscopy data set showing metabolites 
upregulated in hepatocellular carcinoma (upward peaks: Carnitine, anserine, creatine, acetylcarnitine, alpha-ketoglutarate) and downregulated in 
hepatocellular carcinoma (downward pointing peaks: Hippurate, glycine, trimethylamineoxide, creatinine, citrate), compared to urinary nuclear magnetic 
resonance spectroscopy data from patients with cirrhosis. Most metabolites represent alternative energy metabolites as liver tumours are not solely dependent 
on glycolysis for an energy source. HCC: Hepatocellular carcinoma; TMA: Trimethylamineoxide; OPLS: Orthogonal partial least squares discriminant analysis.
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Figure 5  Principal components multivariate statistical analysis (A) and partial least squared discriminant multivariate statistical analysis (B). A: Principal 
components multivariate statistical analysis scatter plot showing statistical separation of data sets of urinary nuclear magnetic (NMR) spectroscopy information 
of hepatocellular carcinoma (HCC) subjects (small black spots), compared to urinary data sets from healthy controls (small green spots); B: Partial least squared 
discriminant multivariate statistical analysis showing statistical differentiation of metabolite information from HCC subjects obtained using NMR spectroscopy, 
compared to similar urinary data sets from patients with cirrhosis. These are the essential raisons d’être for searching and using urinary biomarkers for the early and 
reliable diagnosis of HCC, but promising research is still being undertaken to this end (Figure 6). 
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treatment, whenever available[66­68]. Furthermore, the 
rising trend of prevalence of cholangiocarcinoma in 
Europe, although of uncertain origin[69,70], is a matter of 
serious concern, but the lesson learnt by the long history 
of HCC can be useful for future research and applications. 
CONCLUSION
Urinary biomarkers have been studied for almost half
century, including nucleosides, small proteins, polya­
mines and recently, metabolites. Some of the techniques
and tests described are already suitable for more wide­
spread clinical application, as is the case with ultrasound­
based liver diagnostics, but others, such as urinary 
metabonomics, requires a period of critical evaluation 
or development to take them from the research arena 
to clinical practice. The guidelines of sustainability 
in countries with limited resources, facilities and low 
financial income can be seen as an opportunity for 
addressing research toward low­cost diagnostics and 
for driving clinical practice toward more streamlined 
technology, with ultimate benefits for the populations of 
poorer countries around the world[70]. Also medicine, as 
“science, after all, is essentially international, and it is only 
through lack of the historical sense that national qualities 
have been attributed to it” (Marie Curie). Medicine should 
not exist as a “medical science” with different priorities for 
low and high­income populations[71]. The most important 
discoveries and advancements in the field of medicine 
have required, and probably still require, more focus to 
the clinical problems along with a sustainable analytical 
investigation of all the physiological and pathological 
details.
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